Overview

Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa

Status:
COMPLETED

Trial end date:
2005-02-08

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to evaluate the safety and tolerability of three active doses of nebulized amikacin in a SLIT™ formulation.

Phase:

PHASE1

Details

Lead Sponsor:

Insmed Incorporated